TMCnet News
Finding and Evaluating Oncology Opportunities at BIO Asia 2017- A 1st Oncology Insights Report - Research and MarketsResearch and Markets has announced the addition of the "Finding and Evaluating Oncology Opportunities at BIO Asia 2017- A 1st Oncology Insights Report" report to their offering. This report is a unique resource for finding and evaluating oncology opportunities at the BIO Asia 2017 meeting and is a must read for anyone with an interest in oncology at this exclusive partnering forum. This report features the oncology position and activities of 61 companies identified by the analyst team at 1stOncology. Use this report to make sure you spend your time and resources around BIO Asia where it reaps the most value. Understand in advance from a trustworthy third-party the position of the companies you will meet, the strengths and weaknesses of their pipeline, their partnering position and their recent successes and failures. It includes almost one thousand references detailing the latest positive and negative pipeline development for circa 250 top cancer drugs throughout 2016 to present, giving you a comprehensive insight to current developments such as successful clinical trials, trials with missed primary endpoints, new or terminated partnerships, M&A and much more. To further fuel your ability to actively drive forward your partnering activities, this special BIO Asia 2017 report in oncology also includes circa 300 contacts to business development and licensing people within the featured companies, allowing you to reach out quickly and directly to the right person of interest for initial introductions, partnership discussions, pre-booking meetings etc. This provides you with the ability to review partnering opportunities for close to 900, partnered or as yet un-partnered, rugs in 17 "hot" areas in oncology, including (Number of Drugs in Each Area): - Most recent Positive/Negative Developments (226/43) - Start-Ups (4) - Fierce 15 Drugs (53) - Orphan Drugs (252) - Breakthrough Therapies (31) - Cancer Vaccines (59) - CAR/TCR Therapies (14) - Immune Checkpoints (67) - Epigentic Therapies (35) - Protein Kinase Inhibitors (194) - Antibodies in Oncology (345) - Cancer Peptides (47) - RNA Therapies (13) - Conjugated Drugs (109) - Biomarker/Companion Diagnostic Drugs (166) - Combination Therapy Drugs (492) - Biosimilars/Biobetters (27) Key Topics Covered: 1 Executive Summary 2 About 1stOncology Insights 3 Table of Contents 4 Cancer Companies Participating at BIO Asia 2017 5 Major Recent Developments on Cancer Drugs at BIO Asia from 2016 to Present 6 The Cancer Pipeline of Start-ups 7 Fierce 15 Cancer Drugs 8 Orphan Drugs in Oncology 9 Breakthrough Therapies in Oncology 10 The Immuno-Oncology Pipeline 11 Epigenetic Therapies in Oncology 12 Protein Kinase Inhibitors in Oncology 13 Antibodies in Oncology 14 Cancer Peptides 15 RNA (miRNA, RNAi & siRNA) Therapies in Oncology 16 Conjugated Cancer Drugs 17 Cancer Drugs with Biomarker/Companion Diagnostic Development 18 Cancer Drugs in Combination Therapies 19 Biosimilars and Biobetters in Oncology 20 BD & Licensing Contacts 21 Disclaimer 22 Drug Index 23 Company Index - Abbvie - Ajinomoto - Astellas Pharma - Bayer - BeyondSpring Pharmaceuticals - BioLeaders - BioLite - Boehringer Ingelheim - CStone Pharmaceuticals - Capella Therapeutics - Cue Biopharma - GlaxoSmithKline - Glycostem Therapeutics - Intellia Therapeutics - Interprotein Corporation - Johnsson and Johnsson Innovation - Kyowa Hakko Kirin - Leo Pharma - Maruho - Medigen Biotechnology - Merck Sharp (News - Alert) & Dohme - Mirati Therapeutics - Mitsubishi Tanabe Pharma - Mochida Pharmaceutical - Mundipharma International - Pfizer - PharmaEngine - Pierre Fabre Medicament - Prestige BioPharma - Roivant Sciences - Samyang Biopharmaceuticals - Sanofi - Taisho Pharmaceutical - Zai Lab For more information about this report visit http://www.researchandmarkets.com/research/nsmmpn/finding_and
View source version on businesswire.com: http://www.businesswire.com/news/home/20170307005688/en/ |
